Clinical Trials
128 trialsPD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer
Sun Yat-sen University
Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Peking Union Medical College Hospital
SNMM
Eye & ENT Hospital of Fudan University
A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
China Medical University, China
Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
TopAlliance Biosciences
Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Safety and Efficacy of RX-af01 Combined With PD-1 Antibody
Sun Yat-sen University
SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)
Fujian Cancer Hospital
Chidamide Combined With Toripalimab in Sarcoma
Sun Yat-sen University
Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer
Shouyao Holdings (Beijing) Co. LTD
Toripalimab in Combined With Cetuximab,Chemotherapy for Conversion Therapy of Locally Nonresectable OCSCC
First Affiliated Hospital of Zhejiang University
Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer
Shanghai East Hospital
RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC
RenJi Hospital
Best-EEC
Hebei Medical University Fourth Hospital
Neoadjuvant Toripalimab for dMMR/MSI-H Gastric Cancer
Sun Yat-sen University
HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial
Sun Yat-sen University
Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC
Zhejiang University
Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
BGI, China
Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma
Fudan University
Clinical Study of Chidamide Combined With Toripalimab in the Treatment of Advanced Melanoma
Peking University Cancer Hospital & Institute
Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)
Tianjin Medical University Cancer Institute and Hospital
KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma
Shanghai Kanda Biotechnology Co., Ltd.
Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy
Taizhou Hospital
PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma
Sun Yat-sen University
Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy
Peking Union Medical College Hospital
Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor
Shanghai Pulmonary Hospital, Shanghai, China
Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors
Peking Union Medical College Hospital
Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers
Peking Union Medical College Hospital
Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma
Peking Union Medical College Hospital
Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT
West China Hospital
Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer
Sun Yat-sen University
Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.
Sun Yat-sen University
Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.
Sun Yat-sen University
A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer
Shanghai Junshi Bioscience Co., Ltd.
A Real-World Study of Toripalimab in Chinese Patients With Lung Cancer(THUNDER Study)
Qianfoshan Hospital
HAIC Combined With Toripalimab and Donafenib for Advanced BTC
Fudan University
Thermal Ablation Followed by Immunotherapy for HCC
Xiangya Hospital of Central South University
HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
HIFU
The First Affiliated Hospital with Nanjing Medical University
A Prospective, Single Center Clinical Study of Toripalimab Combined With FLOT Regimen for Perioperative Treatment of PD-L1 Positive Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GEJ)
The First Hospital of Jilin University
Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma
China Medical University, China
An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma
The First Affiliated Hospital of Zhengzhou University
Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Induction Chemotherapy and Toripalimab Followed by Radiotherapy in Unresectable Laryngeal/Hypopharyngeal Carcinoma
Fudan University
A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors
Maxinovel Pty., Ltd.
The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer
Wuhan University